nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—HTR7—vas deferens—testicular cancer	0.129	0.439	CbGeAlD
Lurasidone—HTR7—vein—testicular cancer	0.0549	0.186	CbGeAlD
Lurasidone—HTR2A—vein—testicular cancer	0.0342	0.116	CbGeAlD
Lurasidone—ADRA2C—seminal vesicle—testicular cancer	0.00897	0.0304	CbGeAlD
Lurasidone—ADRA2A—seminal vesicle—testicular cancer	0.00716	0.0243	CbGeAlD
Lurasidone—HTR7—gonad—testicular cancer	0.00705	0.0239	CbGeAlD
Lurasidone—HTR2A—embryo—testicular cancer	0.00648	0.022	CbGeAlD
Lurasidone—ADRA2C—female gonad—testicular cancer	0.00527	0.0179	CbGeAlD
Lurasidone—ADRA2A—gonad—testicular cancer	0.00517	0.0176	CbGeAlD
Lurasidone—HTR7—testis—testicular cancer	0.00508	0.0173	CbGeAlD
Lurasidone—DRD2—testis—testicular cancer	0.00481	0.0163	CbGeAlD
Lurasidone—ADRA2C—testis—testicular cancer	0.00467	0.0159	CbGeAlD
Lurasidone—HTR2A—gonad—testicular cancer	0.0044	0.0149	CbGeAlD
Lurasidone—ADRA2A—female gonad—testicular cancer	0.0042	0.0143	CbGeAlD
Lurasidone—ADRA2A—testis—testicular cancer	0.00373	0.0127	CbGeAlD
Lurasidone—ADRA2C—lymph node—testicular cancer	0.00339	0.0115	CbGeAlD
Lurasidone—HTR2A—testis—testicular cancer	0.00317	0.0108	CbGeAlD
Lurasidone—ADRA2A—lymph node—testicular cancer	0.0027	0.00917	CbGeAlD
Lurasidone—Hypertension—Etoposide—testicular cancer	0.00121	0.00172	CcSEcCtD
Lurasidone—Osteoarthritis—Doxorubicin—testicular cancer	0.00121	0.00171	CcSEcCtD
Lurasidone—Hyperhidrosis—Cisplatin—testicular cancer	0.00121	0.00171	CcSEcCtD
Lurasidone—Pruritus—Bleomycin—testicular cancer	0.0012	0.0017	CcSEcCtD
Lurasidone—Eosinophilia—Methotrexate—testicular cancer	0.00119	0.00169	CcSEcCtD
Lurasidone—Nausea—Vinblastine—testicular cancer	0.00119	0.00169	CcSEcCtD
Lurasidone—Orthostatic hypotension—Epirubicin—testicular cancer	0.00119	0.00169	CcSEcCtD
Lurasidone—Abdominal pain upper—Epirubicin—testicular cancer	0.00119	0.00169	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00119	0.00168	CcSEcCtD
Lurasidone—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00119	0.00168	CcSEcCtD
Lurasidone—Breast disorder—Epirubicin—testicular cancer	0.00118	0.00167	CcSEcCtD
Lurasidone—Hypotension—Cisplatin—testicular cancer	0.00117	0.00166	CcSEcCtD
Lurasidone—Nasopharyngitis—Epirubicin—testicular cancer	0.00117	0.00166	CcSEcCtD
Lurasidone—Abdominal discomfort—Methotrexate—testicular cancer	0.00116	0.00164	CcSEcCtD
Lurasidone—Gastritis—Epirubicin—testicular cancer	0.00116	0.00164	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00115	0.00163	CcSEcCtD
Lurasidone—Abdominal pain—Ifosfamide—testicular cancer	0.00115	0.00162	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00114	0.00161	CcSEcCtD
Lurasidone—Infection—Etoposide—testicular cancer	0.00114	0.00161	CcSEcCtD
Lurasidone—Asthenia—Dactinomycin—testicular cancer	0.00113	0.00161	CcSEcCtD
Lurasidone—Blood creatinine increased—Doxorubicin—testicular cancer	0.00113	0.0016	CcSEcCtD
Lurasidone—Influenza—Epirubicin—testicular cancer	0.00113	0.0016	CcSEcCtD
Lurasidone—Dysphagia—Epirubicin—testicular cancer	0.00113	0.0016	CcSEcCtD
Lurasidone—Dysuria—Methotrexate—testicular cancer	0.00113	0.0016	CcSEcCtD
Lurasidone—Neutropenia—Methotrexate—testicular cancer	0.00113	0.0016	CcSEcCtD
Lurasidone—Tachycardia—Etoposide—testicular cancer	0.00112	0.00158	CcSEcCtD
Lurasidone—Eosinophilia—Epirubicin—testicular cancer	0.00112	0.00158	CcSEcCtD
Lurasidone—Dyspnoea—Cisplatin—testicular cancer	0.00111	0.00158	CcSEcCtD
Lurasidone—Skin disorder—Etoposide—testicular cancer	0.00111	0.00158	CcSEcCtD
Lurasidone—Erectile dysfunction—Methotrexate—testicular cancer	0.00111	0.00157	CcSEcCtD
Lurasidone—Hyperhidrosis—Etoposide—testicular cancer	0.00111	0.00157	CcSEcCtD
Lurasidone—Abdominal pain upper—Doxorubicin—testicular cancer	0.0011	0.00156	CcSEcCtD
Lurasidone—Orthostatic hypotension—Doxorubicin—testicular cancer	0.0011	0.00156	CcSEcCtD
Lurasidone—Angina pectoris—Epirubicin—testicular cancer	0.0011	0.00156	CcSEcCtD
Lurasidone—Breast disorder—Doxorubicin—testicular cancer	0.00109	0.00155	CcSEcCtD
Lurasidone—Decreased appetite—Cisplatin—testicular cancer	0.00109	0.00154	CcSEcCtD
Lurasidone—Diarrhoea—Dactinomycin—testicular cancer	0.00108	0.00153	CcSEcCtD
Lurasidone—Nasopharyngitis—Doxorubicin—testicular cancer	0.00108	0.00153	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00108	0.00153	CcSEcCtD
Lurasidone—Vomiting—Bleomycin—testicular cancer	0.00108	0.00153	CcSEcCtD
Lurasidone—Infestation—Methotrexate—testicular cancer	0.00107	0.00152	CcSEcCtD
Lurasidone—Infestation NOS—Methotrexate—testicular cancer	0.00107	0.00152	CcSEcCtD
Lurasidone—Hypotension—Etoposide—testicular cancer	0.00107	0.00152	CcSEcCtD
Lurasidone—Rash—Bleomycin—testicular cancer	0.00107	0.00152	CcSEcCtD
Lurasidone—Gastritis—Doxorubicin—testicular cancer	0.00107	0.00152	CcSEcCtD
Lurasidone—Dermatitis—Bleomycin—testicular cancer	0.00107	0.00151	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00107	0.00151	CcSEcCtD
Lurasidone—Renal failure—Methotrexate—testicular cancer	0.00106	0.0015	CcSEcCtD
Lurasidone—Neutropenia—Epirubicin—testicular cancer	0.00106	0.0015	CcSEcCtD
Lurasidone—Dysuria—Epirubicin—testicular cancer	0.00106	0.0015	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—testicular cancer	0.00104	0.00148	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—testicular cancer	0.00104	0.00148	CcSEcCtD
Lurasidone—Asthenia—Ifosfamide—testicular cancer	0.00104	0.00147	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—testicular cancer	0.00103	0.00147	CcSEcCtD
Lurasidone—Weight increased—Epirubicin—testicular cancer	0.00103	0.00146	CcSEcCtD
Lurasidone—Pruritus—Ifosfamide—testicular cancer	0.00103	0.00145	CcSEcCtD
Lurasidone—Dyspnoea—Etoposide—testicular cancer	0.00102	0.00145	CcSEcCtD
Lurasidone—Hyperglycaemia—Epirubicin—testicular cancer	0.00102	0.00144	CcSEcCtD
Lurasidone—Somnolence—Etoposide—testicular cancer	0.00102	0.00144	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—testicular cancer	0.00102	0.00144	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—testicular cancer	0.00102	0.00144	CcSEcCtD
Lurasidone—Nausea—Bleomycin—testicular cancer	0.00101	0.00143	CcSEcCtD
Lurasidone—Infestation NOS—Epirubicin—testicular cancer	0.00101	0.00143	CcSEcCtD
Lurasidone—Infestation—Epirubicin—testicular cancer	0.00101	0.00143	CcSEcCtD
Lurasidone—Vomiting—Dactinomycin—testicular cancer	0.00101	0.00143	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—testicular cancer	0.001	0.00142	CcSEcCtD
Lurasidone—Rash—Dactinomycin—testicular cancer	0.000997	0.00141	CcSEcCtD
Lurasidone—Decreased appetite—Etoposide—testicular cancer	0.000995	0.00141	CcSEcCtD
Lurasidone—Diarrhoea—Ifosfamide—testicular cancer	0.000992	0.00141	CcSEcCtD
Lurasidone—Renal failure—Epirubicin—testicular cancer	0.000989	0.0014	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Etoposide—testicular cancer	0.000988	0.0014	CcSEcCtD
Lurasidone—Fatigue—Etoposide—testicular cancer	0.000987	0.0014	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—testicular cancer	0.000978	0.00139	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—testicular cancer	0.000976	0.00138	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—testicular cancer	0.000976	0.00138	CcSEcCtD
Lurasidone—Dizziness—Ifosfamide—testicular cancer	0.000958	0.00136	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—testicular cancer	0.000953	0.00135	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—testicular cancer	0.000951	0.00135	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—testicular cancer	0.00095	0.00135	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—testicular cancer	0.000946	0.00134	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—testicular cancer	0.000942	0.00134	CcSEcCtD
Lurasidone—Nausea—Dactinomycin—testicular cancer	0.000939	0.00133	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—testicular cancer	0.000939	0.00133	CcSEcCtD
Lurasidone—Gastrointestinal pain—Etoposide—testicular cancer	0.000936	0.00133	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—testicular cancer	0.000931	0.00132	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—testicular cancer	0.000931	0.00132	CcSEcCtD
Lurasidone—Vomiting—Ifosfamide—testicular cancer	0.000921	0.00131	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—testicular cancer	0.000919	0.0013	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—testicular cancer	0.000915	0.0013	CcSEcCtD
Lurasidone—Rash—Ifosfamide—testicular cancer	0.000914	0.0013	CcSEcCtD
Lurasidone—Dermatitis—Ifosfamide—testicular cancer	0.000913	0.00129	CcSEcCtD
Lurasidone—Abdominal pain—Etoposide—testicular cancer	0.000905	0.00128	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—testicular cancer	0.000905	0.00128	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—testicular cancer	0.000902	0.00128	CcSEcCtD
Lurasidone—Asthenia—Cisplatin—testicular cancer	0.000896	0.00127	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—testicular cancer	0.000896	0.00127	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—testicular cancer	0.000892	0.00126	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—testicular cancer	0.000887	0.00126	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—testicular cancer	0.000885	0.00126	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00088	0.00125	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—testicular cancer	0.000876	0.00124	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—testicular cancer	0.000869	0.00123	CcSEcCtD
Lurasidone—Nausea—Ifosfamide—testicular cancer	0.000861	0.00122	CcSEcCtD
Lurasidone—Diarrhoea—Cisplatin—testicular cancer	0.000855	0.00121	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—testicular cancer	0.000851	0.00121	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—testicular cancer	0.000845	0.0012	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—testicular cancer	0.000844	0.0012	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—testicular cancer	0.00084	0.00119	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—testicular cancer	0.000838	0.00119	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—testicular cancer	0.000825	0.00117	CcSEcCtD
Lurasidone—Asthenia—Etoposide—testicular cancer	0.000821	0.00116	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—testicular cancer	0.000821	0.00116	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—testicular cancer	0.000819	0.00116	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—testicular cancer	0.000819	0.00116	CcSEcCtD
Lurasidone—Back pain—Methotrexate—testicular cancer	0.000813	0.00115	CcSEcCtD
Lurasidone—Pruritus—Etoposide—testicular cancer	0.00081	0.00115	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—testicular cancer	0.000807	0.00114	CcSEcCtD
Lurasidone—Vomiting—Cisplatin—testicular cancer	0.000794	0.00113	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—testicular cancer	0.000792	0.00112	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—testicular cancer	0.000791	0.00112	CcSEcCtD
Lurasidone—Rash—Cisplatin—testicular cancer	0.000788	0.00112	CcSEcCtD
Lurasidone—Dermatitis—Cisplatin—testicular cancer	0.000787	0.00112	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—testicular cancer	0.000786	0.00111	CcSEcCtD
Lurasidone—Diarrhoea—Etoposide—testicular cancer	0.000783	0.00111	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—testicular cancer	0.000781	0.00111	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—testicular cancer	0.000776	0.0011	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—testicular cancer	0.000776	0.0011	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—testicular cancer	0.000775	0.0011	CcSEcCtD
Lurasidone—Back pain—Epirubicin—testicular cancer	0.00076	0.00108	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—testicular cancer	0.000758	0.00107	CcSEcCtD
Lurasidone—Malaise—Methotrexate—testicular cancer	0.000758	0.00107	CcSEcCtD
Lurasidone—Dizziness—Etoposide—testicular cancer	0.000757	0.00107	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—testicular cancer	0.000756	0.00107	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—testicular cancer	0.000755	0.00107	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—testicular cancer	0.000752	0.00107	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—testicular cancer	0.000746	0.00106	CcSEcCtD
Lurasidone—Nausea—Cisplatin—testicular cancer	0.000742	0.00105	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—testicular cancer	0.000741	0.00105	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—testicular cancer	0.000732	0.00104	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—testicular cancer	0.000728	0.00103	CcSEcCtD
Lurasidone—Vomiting—Etoposide—testicular cancer	0.000728	0.00103	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—testicular cancer	0.000727	0.00103	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—testicular cancer	0.000727	0.00103	CcSEcCtD
Lurasidone—Agitation—Epirubicin—testicular cancer	0.000722	0.00102	CcSEcCtD
Lurasidone—Rash—Etoposide—testicular cancer	0.000722	0.00102	CcSEcCtD
Lurasidone—Dermatitis—Etoposide—testicular cancer	0.000721	0.00102	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—testicular cancer	0.000717	0.00102	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—testicular cancer	0.000715	0.00101	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00071	0.00101	CcSEcCtD
Lurasidone—Malaise—Epirubicin—testicular cancer	0.000709	0.00101	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—testicular cancer	0.000706	0.001	CcSEcCtD
Lurasidone—Syncope—Epirubicin—testicular cancer	0.000705	0.001	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—testicular cancer	0.000704	0.000998	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—testicular cancer	0.000704	0.000998	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—testicular cancer	0.000699	0.000992	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—testicular cancer	0.000691	0.00098	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—testicular cancer	0.000686	0.000972	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—testicular cancer	0.000681	0.000966	CcSEcCtD
Lurasidone—Infection—Methotrexate—testicular cancer	0.000681	0.000966	CcSEcCtD
Lurasidone—Nausea—Etoposide—testicular cancer	0.00068	0.000964	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—testicular cancer	0.000679	0.000962	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—testicular cancer	0.000672	0.000953	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—testicular cancer	0.000672	0.000953	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—testicular cancer	0.000669	0.000949	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—testicular cancer	0.000668	0.000948	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—testicular cancer	0.000667	0.000946	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—testicular cancer	0.000666	0.000944	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000665	0.000942	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—testicular cancer	0.000663	0.00094	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—testicular cancer	0.000656	0.00093	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—testicular cancer	0.000655	0.000928	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—testicular cancer	0.000654	0.000927	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—testicular cancer	0.000652	0.000925	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—testicular cancer	0.000651	0.000923	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—testicular cancer	0.000641	0.000908	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—testicular cancer	0.000639	0.000906	CcSEcCtD
Lurasidone—Infection—Epirubicin—testicular cancer	0.000637	0.000904	CcSEcCtD
Lurasidone—Shock—Epirubicin—testicular cancer	0.000631	0.000895	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—testicular cancer	0.00063	0.000894	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—testicular cancer	0.000629	0.000892	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—testicular cancer	0.000628	0.00089	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—testicular cancer	0.000626	0.000888	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000625	0.000886	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—testicular cancer	0.000623	0.000884	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—testicular cancer	0.00062	0.000879	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—testicular cancer	0.00062	0.000879	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—testicular cancer	0.000619	0.000878	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—testicular cancer	0.000617	0.000875	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000615	0.000872	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—testicular cancer	0.000611	0.000867	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—testicular cancer	0.00061	0.000864	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—testicular cancer	0.000606	0.000859	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—testicular cancer	0.000604	0.000856	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—testicular cancer	0.0006	0.00085	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—testicular cancer	0.000596	0.000845	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000592	0.000839	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—testicular cancer	0.000591	0.000838	CcSEcCtD
Lurasidone—Infection—Doxorubicin—testicular cancer	0.00059	0.000836	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000585	0.000829	CcSEcCtD
Lurasidone—Shock—Doxorubicin—testicular cancer	0.000584	0.000828	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—testicular cancer	0.000582	0.000825	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—testicular cancer	0.00058	0.000823	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—testicular cancer	0.000579	0.000821	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—testicular cancer	0.000577	0.000818	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—testicular cancer	0.000574	0.000814	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—testicular cancer	0.000572	0.000811	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—testicular cancer	0.00057	0.000809	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—testicular cancer	0.000565	0.000801	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—testicular cancer	0.000561	0.000795	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—testicular cancer	0.000558	0.000791	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—testicular cancer	0.000555	0.000786	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000554	0.000785	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—testicular cancer	0.000553	0.000784	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—testicular cancer	0.000542	0.000768	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000541	0.000767	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—testicular cancer	0.000537	0.000761	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—testicular cancer	0.000529	0.00075	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—testicular cancer	0.000528	0.000748	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—testicular cancer	0.000525	0.000744	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—testicular cancer	0.000523	0.000741	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—testicular cancer	0.000516	0.000732	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000513	0.000727	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—testicular cancer	0.000512	0.000726	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—testicular cancer	0.000507	0.000719	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—testicular cancer	0.000492	0.000697	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000485	0.000688	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—testicular cancer	0.000485	0.000688	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—testicular cancer	0.000469	0.000665	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—testicular cancer	0.000469	0.000665	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—testicular cancer	0.00046	0.000653	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—testicular cancer	0.000454	0.000644	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—testicular cancer	0.000453	0.000643	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—testicular cancer	0.000439	0.000622	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—testicular cancer	0.000436	0.000618	CcSEcCtD
Lurasidone—Rash—Methotrexate—testicular cancer	0.000432	0.000613	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—testicular cancer	0.000432	0.000612	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—testicular cancer	0.000426	0.000604	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—testicular cancer	0.000424	0.000602	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—testicular cancer	0.00042	0.000595	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—testicular cancer	0.000408	0.000578	CcSEcCtD
Lurasidone—Nausea—Methotrexate—testicular cancer	0.000407	0.000577	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—testicular cancer	0.000406	0.000576	CcSEcCtD
Lurasidone—Rash—Epirubicin—testicular cancer	0.000405	0.000574	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—testicular cancer	0.000404	0.000573	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—testicular cancer	0.000393	0.000557	CcSEcCtD
Lurasidone—Nausea—Epirubicin—testicular cancer	0.000381	0.00054	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—testicular cancer	0.000377	0.000535	CcSEcCtD
Lurasidone—Rash—Doxorubicin—testicular cancer	0.000374	0.000531	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—testicular cancer	0.000374	0.00053	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—testicular cancer	0.000353	0.0005	CcSEcCtD
